Description: Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Home Page: www.indivior.com
10710 Midlothian Turnpike
North Chesterfield,
VA
23235
United States
Phone:
804 379 1090
Officers
| Name | Title |
|---|---|
| Mr. Mark Crossley | CEO & Exec. Director |
| Mr. Ryan Preblick | CFO & Exec. Director |
| Dr. Christian Heidbreder | Chief Scientific Officer |
| Mr. Jason Thompson | VP of Investor Relations |
| Ms. Cynthia Cetani | Chief Integrity & Compliance Officer |
| Mr. Jeffrey W. Burris | Chief Legal Officer |
| Mr. Jon Fogle | Chief HR Officer |
| Mr. Richard Simkin | Chief Commercial & Strategy Officer |
| Mr. Hillel West | Chief Manufacturing & Supply Officer |
| Ms. Nina DeLorenzo | Chief Global Impact Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 79.44 |
| Price-to-Book MRQ: | 11.9924 |
| Price-to-Sales TTM: | 3.0883 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 900 |